Advertisement.

ANL Projected Dividend Yield

Sponsored ADR Repstg Shs/Adlai Nortye Ltd ( NASDAQ : ANL )

Adlai Nortye is a holding company. Through its subsidiaries, Co. is a biotechnology company focused on the discovery and development of cancer therapies for patients across various tumor types. Co.'s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005. Co.'s main product is AN2025, a pan-phosphoinositide 3-kinase inhibitor that is designed to act against solid tumors. Co.'s preclinical candidates include: AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of B-catenin; and AN9025, an oral small molecule pan-Kirsten rat sarcoma viral oncogene homologue inhibitor.

20 YEAR PERFORMANCE RESULTS

ANL Dividend History Detail
ANL Dividend News
ANL Competitors News

# of Shares: 0

Closing Price: 2.29

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000